American BioScience, Inc.

Abraxane licensed to Taiho Pharmaceutical Co., Ltd., in Japan

Published in Oncology Business Week, December 18th, 2005

American BioScience, Inc., (ABI) announced that it has licensed Abraxane to Taiho Pharmaceutical Co., Ltd., (Taiho) and established a Joint Steering Committee with Taiho which will oversee the development of Abraxane in Japan for the treatment of breast, lung, gastric, and other solid tumors.

Abraxane is being commercialized in North America by Abraxis Oncology, a division of American Pharmaceutical Partners, Inc., (APPX).

Annual taxane sales in Japan are growing with the Japanese market for chemotherapy agents being approximately $3 billion. Taiho, which is based in Tokyo, is part of Otsuka Pharmaceutical, Ltd., one of the largest pharmaceutical...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Oncology Business Week

Source: Oncology Business Week (2005-12-18)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry